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Original Article

Nusinersen versus Sham Control
in Later-Onset Spinal Muscular Atrophy
E. Mercuri, B.T. Darras, C.A. Chiriboga, J.W. Day, C. Campbell, A.M. Connolly,
S.T. Iannaccone, J. Kirschner, N.L. Kuntz, K. Saito, P.B. Shieh, M. Tulinius,
E.S. Mazzone, J. Montes, K.M. Bishop, Q. Yang, R. Foster, S. Gheuens,
C.F. Bennett, W. Farwell, E. Schneider, D.C. De Vivo, and R.S. Finkel,
for the CHERISH Study Group*

A BS T R AC T
BACKGROUND

Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger
RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed
for the treatment of spinal muscular atrophy (SMA).
METHODS

We conducted a multicenter, double-blind, sham-controlled, phase 3 trial of nusinersen in 126 children with SMA who had symptom onset after 6 months of age.
The children were randomly assigned, in a 2:1 ratio, to undergo intrathecal administration of nusinersen at a dose of 12 mg (nusinersen group) or a sham procedure
(control group) on days 1, 29, 85, and 274. The primary end point was the leastsquares mean change from baseline in the Hammersmith Functional Motor Scale–
Expanded (HFMSE) score at 15 months of treatment; HFMSE scores range from
0 to 66, with higher scores indicating better motor function. Secondary end points
included the percentage of children with a clinically meaningful increase from
baseline in the HFMSE score (≥3 points), an outcome that indicates improvement
in at least two motor skills.

The authors’ full names, academic de
grees, and affiliations are listed in the
Appendix. Address reprint requests to
Dr. Mercuri at the Università Cattolica
del Sacro Cuore, Largo Gemelli 8, 00168
Rome, Italy, or at eugeniomaria.mercuri@
unicatt.it.
* A complete list of principal investiga
tors in the CHERISH trial is provided in
the Supplementary Appendix, available
at NEJM.org.
N Engl J Med 2018;378:625-35.
DOI: 10.1056/NEJMoa1710504
Copyright © 2018 Massachusetts Medical Society.

RESULTS

In the prespecified interim analysis, there was a least-squares mean increase from
baseline to month 15 in the HFMSE score in the nusinersen group (by 4.0 points)
and a least-squares mean decrease in the control group (by –1.9 points), with a
significant between-group difference favoring nusinersen (least-squares mean difference in change, 5.9 points; 95% confidence interval, 3.7 to 8.1; P<0.001). This
result prompted early termination of the trial. Results of the final analysis were
consistent with results of the interim analysis. In the final analysis, 57% of the
children in the nusinersen group as compared with 26% in the control group had
an increase from baseline to month 15 in the HFMSE score of at least 3 points
(P<0.001), and the overall incidence of adverse events was similar in the nusinersen
group and the control group (93% and 100%, respectively).
CONCLUSIONS

Among children with later-onset SMA, those who received nusinersen had significant and clinically meaningful improvement in motor function as compared
with those in the control group. (Funded by Biogen and Ionis Pharmaceuticals;
CHERISH ClinicalTrials.gov number, NCT02292537.)
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S

pinal muscular atrophy (SMA) is an
Me thods
autosomal recessive neuromuscular disorder that is characterized by atrophy and Trial Oversight
weakness of the skeletal muscles of the limbs The CHERISH trial protocol (available with the
and trunk and of the bulbar and respiratory full text of this article at NEJM.org) was apmuscles.1,2 It is caused by homozygous deletions proved by the independent review board or ethor loss-of-function mutations in the gene encod- ics committee at each participating site and was
ing survival motor neuron 1 (SMN1) at locus conducted according to the provisions of the
5q13, which result in insufficient expression of Declaration of Helsinki and the International
the survival motor neuron (SMN) protein.1,3-5 A Conference on Harmonisation Good Clinical
paralogous gene, SMN2, also encodes the SMN Practice guidelines. The parents or legal guardprotein, but the level of functional full-length ians of eligible children provided written inSMN protein produced by SMN2 is only 5 to 10% formed consent before participation; the children
of the level produced by SMN1, because a splice- provided assent as appropriate, on the basis of
site variant in SMN2 leads to exclusion of exon institutional guidelines and the child’s age. In
7 from the mature RNA transcript and produc- collaboration with the sponsors (Biogen and Ionis
tion of truncated, dysfunctional SMN protein.5,6 Pharmaceuticals), an independent data and safeNusinersen is a modified antisense oligonucleo ty monitoring board reviewed safety data at
tide drug that resists nucleases and binds to a quarterly intervals, including the results of the
specific sequence within the SMN2 pre–messen- prespecified interim analysis.
The trial was designed by employees of the
ger RNA, thereby modifying the splicing of the
SMN2 pre–messenger RNA to promote the ex- sponsors in collaboration with clinicians who
had experience in the treatment of SMA. Investipression of full-length SMN protein.7-10
The classification system for SMA is based gators collected the data, which were held and
on the age at symptom onset and the most ad- analyzed by Biogen. The authors had access to
vanced motor milestone attained during devel- the complete data set after unblinding, particiopment.5 Patients with a higher SMN2 copy pated in data analysis and interpretation and in
number and a higher level of SMN protein manuscript development, and vouch for the acgenerally have a less severe phenotype.11,12 SMA curacy and completeness of the data. The princitype 1 is characterized by symptom onset by pal investigators vouch for the fidelity of the
6 months of age and failure to sit without sup- study to the protocol and protocol amendments.
port, SMA type 2 by symptom onset between The first draft of the manuscript was written by
6 and 18 months of age and failure to walk the first author and the senior industry author
independently, and SMA type 3 by symptom from Biogen; medical-writing assistance was paid
onset after 18 months of age and an ability to for by Biogen. The sponsors reviewed the manuwalk independently at some point.1,2,5,6,13,14 script and provided feedback to the authors, who
However, these motor milestones can be lost had full editorial control and approved the final
over time.5,15,16 In this trial, we defined later- manuscript for submission.
onset SMA as disease with symptom onset after
6 months of age (most likely to be classified as Patients
SMA type 2 or 3).5 Two earlier open-label trials Key eligibility criteria were genetic documentaand their extensions showed that the adminis- tion of 5q SMA (a homozygous deletion, mutation,
tration of nusinersen did not raise safety con- or compound heterozygote in SMN1) with sympcerns and had a benefit with respect to motor tom onset after 6 months of age, as well as the
function in children with SMA type 2 or 3.9,17 presence of the following features at screening:
We therefore conducted the multicenter, ran- an age of 2 to 12 years, the ability to sit independomized, double-blind, sham-controlled, phase 3 dently, no history of the ability to walk indeCHERISH trial to evaluate the efficacy and pendently (defined as the ability to walk ≥15 ft
safety of nusinersen in children with later- unaided), and a Hammersmith Functional Motor
onset SMA.
Scale–Expanded (HFMSE) score of 10 to 54.
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HFMSE scores range from 0 to 66, with higher
scores indicating better motor function.18,19 Children were not eligible for inclusion in the trial if
they had a severe contracture (i.e., any contracture that could interfere with assessment of the
HFMSE score, according to the investigator), evidence of severe scoliosis on radiography (i.e.,
spine curvature with a Cobb angle of >40 degrees), respiratory insufficiency (i.e., receipt of
invasive or noninvasive ventilation for >6 hours
during a 24-hour period), or a gastric tube placed
to provide adequate nutrition (see the Supplementary Appendix, available at NEJM.org).
Trial Design and Treatment

The trial was conducted at 24 sites in 10 countries and was designed to have a screening period of 4 weeks, a treatment period of 9 months,
and a follow-up period of 6 months. To ensure
balance across the trial groups, the children
were stratified according to age at screening
(<6 years vs. ≥6 years) and then were randomly
assigned, in a 2:1 ratio, to undergo intrathecal
administration of nusinersen at a dose of 12 mg
(nusinersen group) or a sham procedure (control
group). Randomization was performed with the
use of an interactive Web response system.
Nusinersen was administered or the sham procedure was performed by dedicated personnel
who were aware of the group assignments; the
child’s parents and key trial personnel who performed assessments were unaware of the group
assignments until trial completion and were not
present for the procedure. Participants were sedated to avoid any awareness of the procedure.
Treatments that were considered to be necessary
to manage adverse events or provide supportive
care were permitted, in accordance with standardof-care guidelines.20
Trial Procedures and End Points

Nusinersen was administered intrathecally on
days 1, 29, and 85, and a maintenance dose was
administered on day 274. The sham procedure
was performed on the same days; it consisted of
a small needle prick to the lower back, which
was covered with a bandage to simulate the
appearance of a lumbar puncture. Children
were observed at the trial site for at least 24
hours after the first procedure was performed

n engl j med 378;7

and for at least 6 hours after each procedure
thereafter.
The primary end point was the least-squares
mean change from baseline in the total HFMSE
score at month 15. Trained clinical evaluators21
assessed the HFMSE score twice during the
screening period and at 3, 6, 9, 12, and 15
months. The HFMSE is a 33-item measure of
motor function that is specifically validated for
use in patients with SMA to assess activities related to daily living.2,18,19,21,22 Each of the 33 activities is scored on a scale ranging from 0 (no response) to 2 (full response), and total HFMSE
scores range from 0 to 66 points, with an increase in total score indicating an improvement
in motor function.19 A change in the HFMSE
score of at least 3 points is considered to be
clinically meaningful.23
The trial had six secondary end points, including the percentage of children who had an
increase from baseline to month 15 in the
HFMSE score of at least 3 points, the percentage
of children who achieved at least one new World
Health Organization (WHO) motor milestone
(out of a total of six milestones),24 and the
change from baseline in the Revised Upper Limb
Module (RULM) score (which ranges from 0 to
37, with higher scores indicating better function).25 Safety was evaluated throughout the trial
(see the Supplementary Appendix).
Statistical Analysis

We estimated that a sample size of 117 children
would give the trial at least 90% power to detect
a mean (±SD) difference of 3±4.4 points between
trial groups in the change from baseline in the
HFMSE score, at a two-sided alpha level of 0.05.
To control the overall type I error rate at 0.05
across the interim and final analyses for the
primary and secondary end points, a hierarchical strategy with independent alpha spending
functions for primary and secondary end points
was applied26 (see the Supplementary Appendix).
Because the P value for the primary end point
was significant in the interim analysis, this end
point was not formally tested for significance
in the final analysis. All secondary efficacy end
points were assessed in the final analysis.
The prespecified interim analysis of the primary end point was performed in the intention-
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to-treat population, which included patients who
were randomly assigned to a group and underwent at least one assigned procedure (Fig. S1 in
the Supplementary Appendix); this analysis was
conducted when all the children had been enrolled for at least 6 months and at least 39 children had completed their 15-month assessment.
Because some children would not have completed the 15-month assessment by the time of
the interim analysis, the analysis was performed
with the use of a multiple-imputation method to
account for missing data on HFMSE scores obtained after baseline. Least-squares mean values
are reported. In the final analysis, the leastsquares mean changes in the total HFMSE score,
the number of WHO motor milestones achieved
per child, and the RULM score and least-squares
mean differences in change between groups were
based on an analysis of covariance, with group
assignment as a fixed effect and with adjustment
for each child’s age at screening and the value at
baseline.

R e sult s
Patients

A total of 179 children were screened; 126 were
enrolled in the trial, were randomly assigned to
a group, and underwent the assigned procedure
(84 in the nusinersen group, and 42 in the control group) (Fig. S2 in the Supplementary Appendix). The first child underwent the first assigned
procedure on November 24, 2014, and the last
child’s last visit occurred on February 20, 2017.
At the data cutoff date for the prespecified interim analysis (August 31, 2016), 54 children
(43%) had completed the 15-month assessment
and all the children had an HFMSE score that
had been obtained at 6 months or later. In the
prespecified interim analysis, nusinersen showed
efficacy superior to that of the sham procedure;
at the recommendation of the data and safety
monitoring board, we stopped the trial early. All
the children who had not had a 15-month assessment were invited to attend a visit that represented the end of the double-blind period; at this
visit, all assessments that had been scheduled
for the 15-month assessment were performed.
Children who completed the CHERISH trial were
invited to enroll in the open-label extension study
(ClinicalTrials.gov number, NCT02594124), in
which all children were to receive nusinersen.
628
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At the time of the final analysis, no child had
been withdrawn from the trial. A total of 66
children (79%) in the nusinersen group and 34
(81%) in the control group had completed the
15-month assessment; 26 children were enrolled
in the open-label extension study early. At the
15-month assessment or the visit that represented the end of the double-blind period, all the
children had undergone the four assigned procedures, except for 1 child who had received only
three doses of nusinersen before the trial ended
(Fig. S2 in the Supplementary Appendix). The
demographic characteristics of the children at
baseline were similar in the two trial groups;
there were slight differences in age, sex, race,
disease duration, and motor milestones achieved,
but no formal statistical testing was performed.
The stratum that included children younger than
6 years of age was larger than the stratum that
included children 6 years of age or older. A
higher percentage of children in the control
group than in the nusinersen group had achieved
weight-bearing motor milestones, including the
ability to stand alone or walk with support
(Table 1, and Table S1 in the Supplementary
Appendix).
Efficacy

Primary End Point

In the prespecified interim analysis, there was
a least-squares mean increase from baseline to
month 15 in the HFMSE score in the nusinersen
group and a least-squares mean decrease in the
control group, resulting in a significant betweengroup difference favoring nusinersen (leastsquares mean difference in change, 5.9 points;
95% confidence interval [CI], 3.7 to 8.1; P<0.001)
(Table 2). In the final analysis, there was a leastsquares mean increase from baseline to month
15 in the HFMSE score in the nusinersen group
and a least-squares mean decrease in the control
group (least-squares mean difference in change,
4.9 points; 95% CI, 3.1 to 6.7) (Table 2 and
Fig. 1A). Similar results favoring nusinersen
were observed in all sensitivity analyses for the
primary end point and across subgroups defined
according to SMN2 copy number (Tables S2 and
S3 in the Supplementary Appendix).
Greater improvements in total HFMSE score
were observed in the nusinersen group than in
the control group at time points starting after
month 6 (Fig. 1A). At month 15, the greatest

nejm.org

February 15, 2018

The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITY OF WESTERN ONTARIO on July 9, 2018. For personal use only. No other uses without permission.
Copyright © 2018 Massachusetts Medical Society. All rights reserved.

Nusinersen for Later-Onset Spinal Muscular Atrophy

increases from baseline in the HFMSE score had
occurred in the nusinersen group, and the greatest
decreases had occurred in the control group, with
generally similar results observed at months 9
and 12 (Fig. S3 in the Supplementary Appendix).

Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Female sex — no. (%)

Nusinersen
(N = 84)

Control
(N = 42)

46 (55)

21 (50)

Age at screening — yr

Secondary End Points

A higher percentage of children in the nusinersen
group than in the control group had an increase
from baseline to month 15 in the HFMSE score
of at least 3 points (57% vs. 26%, P<0.001) (Table 2, and Fig. S4 in the Supplementary Appendix). The percentage of children who achieved at
least one new WHO motor milestone did not
differ significantly between the nusinersen group
and the control group (20% and 6%, respectively) (Table 2). Because the P value for the
second secondary end point was not significant,
all subsequent analyses of end points in the hierarchical testing strategy were considered to be
exploratory and are not reported. At month 15,
there was a least-squares mean increase from
baseline in the number of new WHO motor
milestones achieved per child in the nusinersen
group (by 0.2) and a least-squares mean decrease
in the control group (by –0.2). There was a leastsquares mean increase from baseline in the
RULM score in the nusinersen group and in the
control group (by 4.2 points and 0.5 points, respectively) (Table 2 and Fig. 1B). The greatest
increases in the RULM score were observed in
the nusinersen group (Fig. S5 in the Supplementary Appendix). The proportion of children who
had achieved the ability to stand alone or walk
with assistance did not differ significantly between groups (Table 2). Analyses of the change
from baseline to month 15 in the HFMSE score
according to age and disease duration revealed
greater improvements in younger children and
in those who received treatment earlier in their
disease course, respectively (Fig. 2). Results of
analyses according to geographic region were
generally consistent with the overall results
(Table S4 in the Supplementary Appendix).
Safety

The overall incidence of adverse events was
similar in the nusinersen group and the control
group (93% and 100%, respectively), as was the
incidence of moderate or severe adverse events
(Table 3). Serious adverse events were reported
in 17% of the children in the nusinersen group
n engl j med 378;7

Median

4.0

3.0

Range

2−9

2−7

Median

10.0

11.0

Range

6−20

6−20

Age at symptom onset — mo

Age at diagnosis of SMA — mo
Median

18.0

18.0

Range

0−48

0−46

Median

39.3

30.2

Range

8−94

10−80

2

6 (7)

4 (10)

3

74 (88)

37 (88)

4

2 (2)

1 (2)

Unknown

2 (2)

0

Ability to sit without support

84 (100)

42 (100)

Ability to walk with support

20 (24)

14 (33)

Disease duration — mo†

SMN2 copy number — no. (%)

Motor milestones ever achieved — no. (%)‡

Ability to walk independently, ≥15 ft
HFMSE score§

0

0

22.4±8.3

19.9±7.2

WHO motor milestones achieved¶

1.4±1.0

1.5±1.0

RULM score‖

19.4±6.2

18.4±5.7

*	Plus–minus values are means ±SD. No formal statistical testing was performed
to assess differences between trial groups in baseline characteristics. Percent
ages may not total 100 because of rounding. SMA denotes spinal muscular
atrophy.
†	Disease duration is a child’s age at screening minus the age at symptom onset.
‡	These data do not reflect the maximal milestone achieved.
§	Hammersmith Functional Motor Scale–Expanded (HFMSE) scores range from
0 to 66, with higher scores indicating better motor function.19
¶	The six World Health Organization (WHO) motor milestones are sitting with
out support, standing with assistance, hands and knees crawling, walking with
assistance, standing alone, and walking alone.24
‖	Revised Upper Limb Module (RULM) scores range from 0 to 37, with higher
scores indicating better function.25

and in 29% in the control group. Some of the
events that were reported as adverse events could
plausibly be linked to SMA and may not reflect
adverse drug effects (Table 3). No child discontinued treatment or was withdrawn from the
trial because of an adverse event. The incidences
of pyrexia, headache, vomiting, back pain, and
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Table 2. Primary and Secondary End Points Assessed at Month 15.*
End Point

Nusinersen
(N = 84)

Control
(N = 42)

Difference

P Value

4.0 (2.9 to 5.1)

–1.9 (–3.8 to 0)

5.9 (3.7 to 8.1)

<0.001

3.9 (3.0 to 4.9)

–1.0 (–2.5 to 0.5)

4.9 (3.1 to 6.7)

—

57 (46 to 68)

26 (12 to 40)

30.5 (12.7 to 48.3)

—

—

6 (2 to 15)‖

Interim analysis†
Primary end point: change from baseline in HFMSE score —
least-squares mean (95% CI)‡
Final analysis§
Primary end point: change from baseline in HFMSE score —
least-squares mean (95% CI)‡
Secondary end points
Children with change in HFMSE score of ≥3 points
% (95% CI)¶
Odds ratio (95% CI)

<0.001

Children who achieved ≥1 new WHO motor milestone
No.

13

2

—

—

20 (11 to 31)

6 (1 to 20)

14 (−7 to 34)

0.08

Change from baseline in number of WHO motor mile
stones achieved — least-squares mean (95% CI)‡

0.2 (0.1 to 0.3)

−0.2 (−0.4 to 0)

0.4 (0.2 to 0.7)

—

Change from baseline in RULM score — least-squares
mean (95% CI)‡

4.2 (3.4 to 5.0)

0.5 (−0.6 to 1.6)

3.7 (2.3 to 5.0)

—

1

1

—

—

2 (0 to 8)

3 (0 to 15)

−1 (−22 to 19)

—

% (95% CI)**

Children who achieved ability to stand alone
No.
% (95% CI)**
Children who achieved ability to walk with assistance
No.
% (95% CI)**

1

0

—

—

2 (0 to 8)

0 (0 to 10)

2 (−19 to 22)

—

*	To control the overall type I error rate at 0.05 across the interim and final analyses for the testing of primary and secondary end points,
a hierarchical strategy was used, in which significance of the primary end point was required before inferential conclusions could be drawn
about the secondary end points. If an end point failed to reach significance, subsequent end points were not tested within the hierarchi
cal analysis. Secondary end points are listed in hierarchical order. Because the P value for the second secondary end point was not signifi
cant, all subsequent end points analyzed in the hierarchical testing strategy were considered to be exploratory. (Details are provided in the
Supplementary Appendix.)
†	The interim analysis of the primary end point was conducted when all the children had been enrolled for at least 6 months and at least
39 children had completed the 15-month assessment. The analysis was performed with the use of a multiple-imputation method. The
number of children with observed data for the 15-month assessment was 35 in the nusinersen group and 19 in the control group, and
the number of children with imputed data was 49 in the nusinersen group and 23 in the control group.
‡	The least-squares mean change and least-squares mean difference in change between groups were based on an analysis of covariance,
with group assignment as a fixed effect and with adjustment for each child’s age at screening and the value at baseline.
§	In the final analysis, the following end points were analyzed with the use of a multiple-imputation method: change from baseline in the
HFMSE score, percentage of children with a change in HFMSE score of at least 3 points, and change from baseline in the RULM score.
Only children with observed data were included in the other analyses. The number of children with observed data for the 15-month assess
ment was 66 in the nusinersen group and 34 in the control group, and the number of children with imputed data was 18 in the nusinersen
group and 8 in the control group.
¶	The percentages and difference (in percentage points) were based on binomial proportions.
‖	This value is an odds ratio instead of a difference. The odds ratio for nusinersen versus control was based on logistic regression, with group
assignment as a fixed effect and with adjustment for each child’s age at screening and the HFMSE score at baseline.
**	The percentages were based on an exact confidence interval, and the differences (in percentage points) on an exact unconditional confi
dence interval.
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Nusinersen (N=84)

Control (N=42)

A
Least-Squares Mean Change from
Baseline in HFMSE Score

5

3.9±0.49

4
3
2
1
0
–1
–2
–3

–1.0±0.76
0

3

6

9

12

15

Months

B

Discussion

5

Least-Squares Mean Change from
Baseline in RULM Score

epistaxis were at least 5 percentage points higher
in the nusinersen group than in the control
group (Table 3). No cases of epistaxis occurred
in the context of abnormal platelet counts, and
there were alternative causes that could explain
these events. The incidences of back pain, headache, and vomiting — known complications of
lumbar puncture27-29 — were at least 5 percentage points higher in the nusinersen group than
in the control group within 72 hours after the
assigned procedure (Table S5 in the Supplementary Appendix). The overall rate of events associated with lumbar puncture (i.e., back pain, cerebrospinal fluid leakage, headache, nausea, the
post–lumbar puncture syndrome, procedural pain,
procedural nausea, procedural headache, and
vomiting) within 24, 72, 120, and 168 hours after the assigned procedure was 9%, 14%, 15%,
and 15%, respectively, in the nusinersen group and
3% for each time period in the control group
(Table S6 in the Supplementary Appendix). There
were no clinically relevant changes related to
nusinersen in clinical laboratory test results (see
the Supplementary Appendix).

4.2±0.40

4
3
2
1

In the CHERISH trial, among children with later0
onset SMA, significant improvement in motor
0.5±0.56
function was observed with nusinersen treat–1
ment as compared with a sham procedure. Per0
3
6
9
12
15
sons with later-onset SMA and their caregivers
Months
indicated that stabilization of their current state
Figure 1. Change Over Time in the Hammersmith Functional Motor Scale–
would meet their therapeutic expectations and
Expanded Score and the Revised Upper Limb Module Score (Final Analysis).
represent a clinically meaningful response.22,30
Shown is the least-squares mean change from baseline to the time of each
In this trial, as in the ENDEAR trial for infantrial assessment in the Hammersmith Functional Motor Scale–Expanded
tile-onset SMA (most likely to be classified as
(HFMSE) score (Panel A) and in the Revised Upper Limb Module (RULM)
31
SMA type 1), we found that nusinersen had the
score (Panel B) in the final analysis. HFMSE scores range from 0 to 66, with
capacity to produce meaningful changes in the
higher scores indicating better motor function19; a change in the HFMSE
score of at least 3 points is considered to be clinically meaningful.23 RULM
clinical course of SMA. In this trial, more than
scores range from 0 to 37, with higher scores indicating better function.25
half the children in the nusinersen group had
I bars indicate standard errors.
an increase from baseline to month 15 in the
HFMSE score of at least 3 points (i.e., a clinically meaningful improvement),23 which is uncommon among children with later-onset SMA.32,33 HFMSE score over the 15-month period were
The final results were consistent with the in- observed in younger children and in those who
terim results. The greatest improvements in the received treatment soon after symptom onset.
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In the control group, there was improvement
in the least-squares mean HFMSE score until
A
month 6, after which the difference in change
15
between the nusinersen group and the control
group became more apparent. Least-squares
10
mean changes in the HFMSE score in the control
group were largely confined to a ±2-point range
5
over the 15-month period, a finding similar to
observations in a nonambulant natural-history
0
cohort over a 12-month period.32 The short-lived
improvements observed in the control group
–5
during the first months of the treatment period
probably resulted from a combination of the
–10
placebo effect, the learning curve for the assessment of the HFMSE and RULM scores, and ini–15
2
4
6
8
tial developmental gains, particularly in younger
children.32 Some children in the control group
Age (yr)
had a decrease in the HFMSE score of up to 10
B
points, a finding that is consistent with results
15
in a recent retrospective study,32 but those treated with nusinersen had a more stable course.
10
No new safety concerns were identified.9,10,31
Back pain and headache are common after lum5
bar puncture, occurring in up to one third of
children who undergo the procedure,27,34 a rate
0
that is consistent with the incidences of these
adverse events within 72 hours after lumbar
–5
puncture in the nusinersen group in this trial.
The overall rate of adverse events associated with
–10
lumbar puncture observed in the nusinersen
group in this trial (9 to 15% within 24 to 168
–15
2
4
6
8
hours after lumbar puncture) was similar to
Disease Duration (yr)
rates reported in the literature (8 to 25%).35-38
This trial had some limitations. For example,
Figure 2. Change from Baseline to Month 15 in Individual HFMSE Scores
the strict eligibility criteria (i.e., no severe conAccording to Age and Disease Duration at Screening (Final Analysis).
tractures or scoliosis, outlying HFMSE scores,
Shown is the change from baseline to month 15 in each child’s HFMSE
respiratory insufficiency, or reliance on a gastric
score according to age (Panel A) and disease duration (Panel B) at screening
tube) meant that the enrolled population was
in the final analysis. Disease duration is a child’s age at screening minus
the age at symptom onset. The analyses included children in the intentionmore homogeneous and younger than the poputo-treat population who did not have missing data for the 15-month assess
lation that is encountered in the clinical-practice
ment (66 in the nusinersen group, and 34 in the control group). The dotted
setting. In the trial, 16% of the enrolled children
lines indicate a 3-point change in the HFMSE score, which is considered to
were 6 years of age or older.
23
be clinically meaningful.
The results we report here are consistent with
the results of previous open-label studies that
The ENDEAR trial also showed greater improve- enrolled children up to 15 years of age. The
ments in infants who received treatment with studies showed that nusinersen had positive
nusinersen earlier in their disease course than effects in populations of children with SMA
in those who received later treatment.31
type 2 or 3 that were broader and more heteroControl (N=34)

Change from Baseline to Month 15
in HFMSE Score

Change from Baseline to Month 15
in HFMSE Score

Nusinersen (N=66)
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Table 3. Summary of Adverse Events.*
Nusinersen
(N = 84)

Event

Control
(N = 42)

no. of patients (%)
Any adverse event

78 (93)

42 (100)

Any moderate or severe adverse event

39 (46)

23 (55)

Any severe adverse event

4 (5)

3 (7)

Any serious adverse event

14 (17)

12 (29)

Any adverse event leading to treatment discontinuation

0

0

Any adverse event leading to withdrawal from the trial

0

0

Adverse events with the highest incidence†
Pyrexia

36 (43)

15 (36)

Upper respiratory tract infection‡

25 (30)

19 (45)

Headache

24 (29)

3 (7)

Vomiting

24 (29)

5 (12)

Back pain

21 (25)

0

Cough‡

21 (25)

9 (21)

Nasopharyngitis‡

20 (24)

15 (36)

2 (2)

6 (14)

Serious adverse events with the highest incidence§
Pneumonia‡
Influenza‡

0

2 (5)

2 (2)

2 (5)

Fecaloma

0

2 (5)

Dehydration

0

2 (5)

36 (43)

15 (36)

Respiratory distress‡

Adverse events with an incidence ≥5 percentage points higher
in the nusinersen group than in the control group¶
Pyrexia
Headache

24 (29)

3 (7)

Vomiting

24 (29)

5 (12)

Back pain

21 (25)

0

Epistaxis

6 (7)

0

*	Investigators rated the severity of each adverse event (mild, moderate, or severe). Moderate adverse events were de
fined as events that caused discomfort and interrupted the child’s usual daily activities. Severe adverse events were
defined as events that caused severe discomfort or incapacitation or had a substantial effect on daily life. Investigators
reported an adverse event as a serious adverse event if it met the following criterion: any untoward medical occurrence
that resulted in death or a risk of death, hospitalization or prolonged hospitalization, persistent or substantial disability
or incapacitation, or a congenital anomaly or birth defect. Reporting of serious adverse events and rating of the severity
of each adverse event were conducted separately, on the basis of the criteria for each type of adverse event. For partici
pants who reported more than one adverse event, only one event of the highest severity was counted in the total inci
dence.
†	The events, classified according to Medical Dictionary for Regulatory Activities (MedDRA) preferred terms, occurred in
at least 20% of children in either trial group.
‡	The events could plausibly be linked to spinal muscular atrophy.
§	The events, classified according to MedDRA preferred terms, occurred in at least 5% of children in either trial group.
¶	The events were classified according to MedDRA preferred terms. A child was counted only once within each category.
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